IP Library Granted Patent US 11,093,883
Granted Patent B2
US 11,093,883 · App. 16/104,790 · Granted Aug 17, 2021

Apparatus, method, and computer-readable medium for determining a drug for manufacture

Inventors: Xiaodong Zhou (San Francisco, CA); ShengLei Cao (San Francisco, CA); Matthew Edward Sparrowhawk (London, GB); Laura Vitez (San Francisco, CA); Romeo Radman (London, GB); Karthik Subramanian (London, GB); Michael Collingsworth (London, GB); Jean-Sebastien Brien (San Francisco, CA)
Assignee: CAMELOT UK BIDCO LIMITED
G06Q10/06375G06Q10/067G06Q50/04G16H10/20G16H50/00G16H50/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,093,883
App. No.
16/104,790
Granted
Aug 17, 2021
Kind
B2
Abstract

An apparatus, method, and computer readable medium for determination of a drug for manufacture. The apparatus includes processing circuitry configured to receive input data related to one or more drug programs, acquire data from a database, generate one or more models based upon the acquired data from the database, determine, from the one or more models, one or more outputs related to the chronological event, select, based upon the determined one or more outputs, one of the one or more drug programs for manufacture, and transmit, to the manufacturing device via the network, manufacturing information related to the manufacture of the selected one of the one or more drug programs.

Claims (49)

1. An apparatus for determining a drug for manufacture, the apparatus being communicably coupled via a network to a manufacturing device, the apparatus comprising:

processing circuitry configured to

receive input data related to candidate drug programs, the input data describing, for each candidate drug program, a candidate drug, a disease indication, and a geo location associated with a development of the candidate drug,

acquire data from a database based upon the input data, wherein the acquired data comprises chronological data and qualitative data of historical drug programs related to each candidate drug program, the qualitative data describing characteristics of clinical trials associated with the historical drug programs,

generate, for each candidate drug program, at least one success model and at least one timeline model based on the acquired data from the database related to the historical drug programs, each of the at least one success model and the at least one timeline model being related to chronological events of the clinical trials associated with the historical drug programs, the chronological events being one or more milestone dates that define the clinical trials, wherein

each of the at least one success model is a logistic regression model including, as parameters thereof, a subset of characteristics of a respective clinical trial determined to positively affect a likelihood function defining the logistic regression model, and

each of the at least one timeline model is a proportional hazard model including, as parameters thereof, a subset of characteristics of a respective clinical trial determined to positively affect a likelihood function defining the proportional hazard model,

determine, from a composite of the at least one success model and a corresponding composite of the at least one timeline model for each candidate drug program, one or more outputs related to a corresponding chronological event for each of the candidate drug programs,

select, based upon the determined one or more outputs for each of the candidate drug programs, one of the candidate drug programs for manufacture, and

transmit, to the manufacturing device via the network, manufacturing information related to the manufacture of the candidate drug associated with the selected one of the candidate drug programs, the manufacturing device beginning the manufacture of the candidate drug upon receipt of the manufacturing information from the apparatus, wherein

the composite of the at least one success model predicts a probability that a respective candidate drug program will reach a particular milestone date of a respective clinical trial, and

the corresponding composite of the at least one timeline model predicts a time required for the respective candidate drug program to reach the particular milestone date of the respective clinical trial.

2. The apparatus according to claim 1 , wherein the processing circuitry is configured to select the selected one of the candidate drug programs for manufacture by

comparing, as the one or more outputs for the candidate chug programs, a success probability that each candidate drug program will reach the particular milestone and a time required for each candidate drug program to reach the particular milestone.

3. The apparatus according to claim 2 , wherein the processing circuitry is configured to select, based on the comparing and as the selected one of the candidate drug programs for manufacture, a candidate drug program that maximizes a success probability that a respective candidate drug program will reach a particular milestone.

4. The apparatus according to claim 1 , wherein coefficients of the parameters of the logistic regression model are optimized via a maximum likelihood estimator.

5. The apparatus according to claim 1 , wherein coefficients of the parameters of the proportional hazard model are optimized via a maximum likelihood estimator.

6. A method for determining a drug for manufacture, comprising:

receiving, by processing circuitry, input data related to candidate drug programs, the input data describing, for each candidate drug program, a candidate drug, a disease indication, and a geo location associated with a development of the candidate drug;

acquiring, by the processing circuitry, data from a database based upon the input data, wherein the acquired data comprises chronological data and qualitative data of historical drug programs related to each candidate drug program, the qualitative data describing characteristics of clinical trials associated with the historical drug programs;

generating, by the processing circuitry and for each candidate drug program, at least one success model and at least one timeline model based on the acquired data from the database related to the historical drug programs, each of the at least one success model and the at least one timeline model being related to chronological events of the clinical trials associated with the historical drug programs, the chronological events being one or more milestone dates that define the clinical trials, wherein

each of the at least one success model is a logistic regression model including, as parameters thereof, a subset of characteristics of a respective clinical trial determined to positively affect a likelihood function defining the logistic regression model, and

each of the at least one timeline model is a proportional hazard model including, as parameters thereof, a subset of characteristics of a respective clinical trial determined to positively affect a likelihood function defining the proportional hazard model;

determining, by the processing circuitry, from a composite of the at least one success model and a corresponding composite of the at least one timeline model for each candidate drug program, one or more outputs related to a corresponding chronological event for each of the candidate drug programs;

selecting, by the processing circuitry, based upon the determined one or more outputs for each of the candidate drug programs, one of the candidate drug programs for manufacture; and

transmitting, by the processing circuitry, to a manufacturing device via a network, manufacturing information related to the manufacture of the candidate drug associated with the selected one of the candidate drug programs, the manufacturing device beginning the manufacture of the candidate drug upon receipt of the manufacturing information, wherein

the composite of the at least one success model predicts a probability that a respective candidate drug program will reach a particular milestone date of a respective clinical trial, and

the corresponding composite of the at least one timeline model predicts a time required for the respective candidate drug program to reach the particular milestone date of the respective clinical trial.

7. The method according to claim 6 , wherein the selecting, by the processing circuitry, further comprises

comparing, as the one or more outputs for the candidate drug programs, a success probability that each candidate drug program will reach the particular milestone and a time required for each candidate drug program to reach the particular milestone.

8. The method according to claim 7 , wherein the selecting selects, based on the comparing as the selected one of the candidate drug programs for manufacture, a candidate drug program that maximizes a success probability that a respective candidate drug program will reach a particular milestone.

9. The method according to claim 6 , wherein coefficients of the parameters of the logistic regression model are optimized via a maximum likelihood estimator.

10. The method according to claim 6 , wherein coefficients of the parameters of the proportional hazard model are optimized via a maximum likelihood estimator.

11. A non-transitory computer-readable storage medium storing computer-readable instructions that, when executed by a computer, cause the computer to perform a method of determining a drug for manufacture, comprising:

receiving input data related to candidate drug programs, the input data describing a candidate drug, a disease indication, and a geo location associated with a development of the candidate drug;

acquiring data from a database based upon the input data, wherein the acquired data comprises chronological data and qualitative data of historical drug programs related to each candidate drug program, the qualitative data describing characteristics of clinical trials associated with the historical drug programs;

generating, for each candidate drug program, at least one success model and at least one timeline model based on the acquired data from the database related to the historical drug programs, each of the at least one success model and the at least one timeline model being related to chronological events of the clinical trials associated with the historical drug programs, the chronological events being one or more milestone dates that define the clinical trials, wherein

each of the at least one success model is a logistic regression model including, as parameters thereof, a subset of characteristics of a respective clinical trial determined to positively affect a likelihood function defining the logistic regression model, and

each of the at least one timeline model is a proportional hazard model including, as parameters thereof, a subset of characteristics of a respective clinical trial determined to positively affect a likelihood function defining the proportional hazard model;

determining, from a composite of the at least one success model and a corresponding composite of the at least one timeline model for each candidate drug program, one or more outputs related to a chronological event for each of the candidate drug programs;

selecting, based upon the determined one or more outputs for each of the candidate drug programs, one of the candidate drug programs for manufacture; and

transmitting, to a manufacturing device via a network, manufacturing information related to the manufacture of the candidate drug associated with the selected one of the candidate drug programs, the manufacturing device beginning the manufacture of the candidate drug upon receipt of the manufacturing information, wherein

the composite of the at least one success model predicts a probability that a respective candidate drug program will reach a particular milestone date of a respective clinical trial, and

the corresponding composite of the at least one timeline model predicts a time required for the respective candidate drug program to reach the particular milestone date of the respective clinical trial.

12. The non-transitory computer-readable storage medium according to claim 11 , wherein the selecting further comprises

comparing, as the one or more outputs for the candidate chug programs, a success probability that each candidate drug program will reach the particular milestone and a time required for each candidate drug program to reach the particular milestone.

13. The non-transitory computer-readable storage medium according to claim 12 , wherein the selecting selects, based on the comparing as the selected one of the candidate drug programs for manufacture, a candidate drug program that maximizes a success probability that a respective candidate drug program will reach a particular milestone.

14. The non-transitory computer-readable storage medium according to claim 11 , wherein coefficients of the parameters of the logistic regression model are optimized via a maximum likelihood estimator.

15. The non-transitory computer-readable storage medium according to claim 11 , wherein coefficients of the parameters of the proportional hazard model are optimized via a maximum likelihood estimator.

Assignments (7)
SECURITY INTEREST Recorded Dec 3, 2021
From: DECISION RESOURCES, INC.; DR/DECISION RESOURCES, LLC; CPA GLOBAL (FIP) LLC; CPA GLOBAL PATENT RESEARCH LLC; INNOGRAPHY, INC.; CAMELOT UK BIDCO LIMITED
To: WILMINGTON TRUST, NATIONAL ASSOCATION
Reel/Frame 058907/0091 →
SECURITY INTEREST Recorded Dec 17, 2019
From: CAMELOT UK BIDCO LIMITED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 051323/0875 →
SECURITY INTEREST Recorded Dec 17, 2019
From: CAMELOT UK BIDCO LIMITED
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 051323/0972 →
SECURITY INTEREST Recorded Nov 1, 2019
From: CAMELOT UK BIDCO LIMITED
To: BANK OF AMERICA, N.A.
Reel/Frame 050906/0284 →
SECURITY INTEREST Recorded Nov 1, 2019
From: CAMELOT UK BIDCO LIMITED
To: WILMINGTON TRUST, N.A. AS COLLATERAL AGENT
Reel/Frame 050906/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2018
From: SPARROWHAWK, MATTHEW EDWARD; COLLINGSWORTH, MICHAEL
To: CAMELOT UK BIDCO LIMITED
Reel/Frame 046787/0613 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2018
From: ZHOU, XIAODONG; CAO, SHENGLEI; VITEZ, LAURA; RADMAN, ROMEO; SUBRAMANIAN, KARTHIK; BRIEN, JEAN-SEBASTIEN
To: CAMELOT UK BIDCO LIMITED
Reel/Frame 046679/0289 →